Abciximab
Also known as: 7E3 Fab, Abciximab, Anti-GPIIb/IIIa antibody fragment, c7E3, c7E3 Fab, ReoPro
Source Abciximab at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Abciximab is a chimeric Fab fragment of a monoclonal antibody that blocks the platelet glycoprotein IIb/IIIa (αIIbβ3) integrin. It is approved for intravenous use to inhibit platelet aggregation during percutaneous coronary intervention (PCI) and in acute coronary syndromes, helping to reduce thrombotic complications.
Mechanism of Action
The Fab fragment binds the GP IIb/IIIa receptor on activated platelets with high affinity (Kd ≈ 6.2 nM), occupying the fibrinogen‑binding site and preventing cross‑linking of platelets. This interruption of the final common pathway of platelet aggregation curtails thrombus formation. The effect is rapidly reversible with platelet transfusion, and the drug does not require renal dose adjustment.
What the Research Shows
Clinical studies from the late 1990s showed that GP IIb/IIIa inhibition with abciximab lowered ischemic complications during PCI for both NSTE‑ACS and STEMI. A 2012 meta‑analysis of seven RCTs (n≈3,300) found no mortality advantage of intracoronary versus intravenous delivery, and the apparent reduction in recurrent MI vanished when one trial was removed. A phase IV registry of 500 patients demonstrated that repeat abciximab dosing after ≥7 days is generally safe, though profound thrombocytopenia occurred more often than in historical controls. Review articles highlight abciximab’s strong guideline endorsement for primary PCI in STEMI, its lack of renal dosing needs, and its reversible platelet inhibition. Experimental work attaches abciximab to ultrasound microbubbles for molecular imaging of arterial thrombus.
Reported Benefits
Evidence supports abciximab’s ability to reduce periprocedural myocardial necrosis and other ischemic events during PCI, especially in high‑risk settings such as STEMI. Guideline panels give it the highest recommendation among GP IIb/IIIa inhibitors for primary PCI. Its rapid, reversible action and absence of renal dosing requirements add practical advantages, and repeat administration can be performed safely in selected patients.
Limitations of the Evidence
Meta‑analyses do not demonstrate a clear mortality benefit of intracoronary over standard intravenous infusion, and the benefit on recurrent MI is inconsistent. Bleeding and thrombocytopenia, including rare profound cases, limit its use. Newer antiplatelet agents have supplanted abciximab in many contemporary STEMI protocols, and most data derive from studies conducted before widespread use of newer drugs, leaving gaps in current comparative effectiveness.
Safety Considerations
The most common adverse effects are bleeding and thrombocytopenia; profound thrombocytopenia has been reported more frequently with repeat dosing. Anaphylactic reactions, though rare, have been described. Monitoring platelet counts and signs of hemorrhage is essential during and after infusion. Platelet transfusion can reverse the antiplatelet effect if severe bleeding occurs.
How It Is Administered
Abciximab is administered intravenously, typically as an initial bolus followed by a continuous infusion. Intracoronary delivery has been explored in clinical trials but is not standard practice. The drug is supplied as a sterile solution for IV use and does not require dose adjustment for renal impairment.
Routes of Administration
Goals & Uses
- Adjunct in primary PCI for STEMICardiovascular / Acute Coronary SyndromeModerate
- Prevent periprocedural thrombotic eventsAntiplatelet TherapyHigh
- Adjunct therapy in unstable angina refractory to conventional treatmentCardiovascular / AntiplateletHigh
- Reduce incidence of myocardial infarctionCardiovascularHigh
- Prevent periprocedural thrombosisAntithromboticHigh
- Reduction of acute myocardial infarction in PCI patientsCardiovascularHigh
- Stent thrombosis preventionCardiovascular / Interventional CardiologyHigh
- Prevention of ischemic complications during PCICardiovascular / AntiplateletHigh
Contraindications
- Oral anticoagulant therapy within 7 days (unless PT ≤1.2× control)Drug Interaction / Bleeding RiskHigh
- History of stroke within 2 years or any stroke with significant residual neurological deficitNeurological / Bleeding RiskHigh
- Known hypersensitivity to murine proteins or abciximabImmunologicalHigh
- Active internal bleedingBleeding RiskHigh
- Recent (≤30 days) ischemic stroke or intracranial hemorrhageNeurologicHigh
- Thrombocytopenia (platelet count < 100,000 cells/μL)HematologicalHigh
- Severe uncontrolled hypertensionCardiovascularModerate
- Recent major surgery or trauma (within 6 weeks)Surgical / Bleeding RiskHigh
- Recent (within 30 days) ischemic strokeNeurologicHigh
Adverse Effects
- Nausea / VomitingGastrointestinalCommon
- Hypersensitivity / anaphylaxisImmunologicalRare
- ThrombocytopeniaHematologicUncommonLow platelet count
- Bleeding (major and minor)HematologicalCommon
- HypotensionCardiovascularUncommonLow blood pressure
- BleedingHematologicCommonAbnormal bleeding or hemorrhage
- Back painMusculoskeletalCommonPain in the back
Drug Interactions
- HeparinHigh
- DextranModerate
- AspirinModerate
- Oral antiplatelet agents (aspirin, clopidogrel)Moderate
- Low molecular weight heparins (LMWH)Moderate
- Thrombolytics (e.g., alteplase, streptokinase)High
- Glycoprotein IIb/IIIa inhibitors (e.g., tirofiban, eptifibatide)High
- Unfractionated HeparinHigh
- Other GPIIb/IIIa inhibitors (e.g., eptifibatide, tirofiban)High
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Prior abciximab exposureImmunologicalRelative
- Pediatric patientsAgeRelative
- Renal impairment (CrCl <30 mL/min)RenalRelative
- Patients with severe hepatic impairmentHepaticRelative
- Elderly patients (≥65 years)Age RelatedRelative
- Elderly (>75 years)GeriatricRelative
Regulatory Status
- European UnionApprovedApproved: Prevention of cardiac ischemic complications during PCIEMA approval; same dosing regimen as US.
- United StatesApprovedApproved: Adjunct to coronary artery bypass grafting, Adjunct to percutaneous coronary interventionFDA approved; administered IV as a bolus followed by infusion.
- United KingdomApprovedApproved: Adjunct to percutaneous coronary interventionAvailable via NHS formularies.
Approved in the US (FDA) and EU for use in coronary artery disease procedures; administered as a short‑infusion.
Evidence & Sources
- Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z
- Journal ArticleModerateUsta C, Turgut NT, Bedel A2016-01-01T00:00:00.000000Z
- Journal ArticleHighKubica J, et al.2012-01-01T00:00:00.000000Z
- Journal ArticleModerateOrford JL, Holmes DR Jr2002-01-01T00:00:00.000000Z
- Journal ArticleModerateMazzaferri EL Jr, Young JJ2008-01-01T00:00:00.000000Z
Frequently Asked Questions
What clinical situations warrant the use of abciximab?
Abciximab is indicated for patients undergoing percutaneous coronary intervention, particularly during acute coronary syndromes such as STEMI, where rapid inhibition of platelet aggregation can lower the risk of procedural thrombotic complications.
How does abciximab differ from other GP IIb/IIIa inhibitors?
Compared with small‑molecule inhibitors like eptifibatide and tirofiban, abciximab is a Fab fragment with a higher binding affinity for the GP IIb/IIIa receptor and does not require renal dose adjustment. It also has a longer platelet‑bound half‑life, making its antiplatelet effect more durable but potentially increasing bleeding risk.
Can abciximab be given more than once to the same patient?
A phase IV registry of 500 patients showed that repeat administration after at least seven days is generally safe and effective, though it may increase the incidence of profound thrombocytopenia. Careful monitoring is advised if repeat dosing is considered.
Is intracoronary administration of abciximab more effective than the standard IV route?
A meta‑analysis of randomized trials found no clear mortality advantage for intracoronary delivery, and the observed reduction in recurrent myocardial infarction was not consistent after sensitivity analysis. Current evidence does not support routine intracoronary use over the standard intravenous infusion.
What are the main safety concerns with abciximab therapy?
The primary safety issues are bleeding and thrombocytopenia, including occasional profound platelet drops. Rare anaphylactic reactions have also been reported. Monitoring platelet counts and clinical signs of bleeding is essential, and platelet transfusion can reverse its effect if needed.
What is Abciximab?
Abciximab is a chimeric Fab fragment of a monoclonal antibody that blocks the platelet glycoprotein IIb/IIIa (αIIbβ3) integrin. It is approved for intravenous use to inhibit platelet aggregation during percutaneous coronary intervention (PCI) and in acute coronary syndromes, helping to reduce thrombotic complications.
What is Abciximab used for?
Abciximab is educationally associated with: Adjunct in primary PCI for STEMI, Prevent periprocedural thrombotic events, Adjunct therapy in unstable angina refractory to conventional treatment, Reduce incidence of myocardial infarction, Prevent periprocedural thrombosis, Reduction of acute myocardial infarction in PCI patients, Stent thrombosis prevention, Prevention of ischemic complications during PCI. Educational only — not medical advice.
How is Abciximab administered?
Recorded routes of administration: Intravenous.
What are the potential side effects of Abciximab?
Reported adverse effects include: Nausea / Vomiting, Hypersensitivity / anaphylaxis, Thrombocytopenia, Bleeding (major and minor), Hypotension, Bleeding, Back pain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Abciximab?
Recorded contraindications: Oral anticoagulant therapy within 7 days (unless PT ≤1.2× control), History of stroke within 2 years or any stroke with significant residual neurological deficit, Known hypersensitivity to murine proteins or abciximab, Active internal bleeding, Recent (≤30 days) ischemic stroke or intracranial hemorrhage, Thrombocytopenia (platelet count < 100,000 cells/μL), Severe uncontrolled hypertension, Recent major surgery or trauma (within 6 weeks), Recent (within 30 days) ischemic stroke. Consult a qualified clinician before use.